Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
Date:4/1/2009

by patients than Schedule A, while maintaining anti-leukemic activity. Ten of 35 patients on Schedule B have achieved CR or CRp. In addition to improved tolerability, the 30-day all-cause mortality has been reduced to 9%. To date, 16 of the planned 30 patients have been enrolled in Schedule C.
  • Presented interim clinical data of the Phase 1b/2 trial of voreloxin combined with cytarabine in relapsed/refractory AML at the 50th Annual Meeting of the American Society of Hematology, with a year end update that coincided with the 27th Annual J.P. Morgan Healthcare Conference in San Francisco. A maximum tolerated dose of 80 mg/m2 of voreloxin was established for Schedule A (continuous infusion of cytarabine), with 9 CRs or CRps reported in the Phase 1b dose escalation. Early data show that six of fourteen evaluable AML patients in first relapse enrolled in the Phase 2 portion of Schedule A of this trial have achieved CR, with a preliminary 30-day all-cause mortality of less than 10%. In addition, one patient who achieved a partial response proceeded to bone marrow transplant. Enrollment for Schedule A is complete. In Schedule B (a 2 hour intravenous infusion of cytarabine), the third dose escalation cohort, with a dose of 90 mg/m2 of voreloxin, is fully enrolled. Complete remissions have been observed in Schedule B in both relapsed and treatment refractory patients. Enrollment into the Phase 2 portion of Schedule B is expected to begin shortly.
  • Presented updated interim data from an ongoing Phase 2 clinical trial of single-agent voreloxin in platinum-resistant ovarian cancer patients at the 12th Biennial Meeting International Gynecologic Cancer Society, with a year end update that coincided with the 27th Annual J.P. Morgan Healthcare Conference in San Francisco. Three schedules of voreloxin have been studied, 48 mg/m2 given every three weeks (N=65), and 60 mg/m2 (N=37) and 75 mg/m2 (N=35) given every four weeks. Enrollment of this trial comp
    '/>"/>

  • SOURCE Sunesis Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
    2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
    4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
    5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
    6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
    7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
    8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
    9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
    10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
    11. Sunesis to Present at Upcoming Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... 15, 2014 ­ RedBrick Health , a fast-growing ... today announces that EmblemHealth , the ... is now providing the RedBrick Compass health assessment, combined ... all of its members. EmblemHealth is among the first ...
    (Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how ... latent viruses is the Epstein Barr Virus (EBV), and one ... is a chronic inflammatory disease that destroys the body’s joints. ... patients have high concentrations of EBV DNA in their bodies ...
    (Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
    (Date:1/14/2014)... BURLINGAME, Calif. , Jan. 14, 2014 As pet owners ... no doubt many of them wrote: "Take better care of my ... and even designer clothes and top-brand carrying cases to take the ... Pet parents might also feel compelled to buy some pricey toys ...
    Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
    ... , , , ... 28 Avid Bioservices, Inc., a leading provider of cGMP contract manufacturing ... strengthened its executive team with the appointments of Truc Le as chief ... These additions reflect Avid,s recent successes in expanding its customer base and ...
    ... , Strategic Examination and Consolidation of Services ... Aug. 27 Little uniformity exists in the structure or functions ... according to Clinical Trials Offices: What,s New in Research ... Centers (AAHC). Emerging centralized clinical trial offices (CTOs) are among ...
    ... , , , , BETHLEHEM, ... , (Logo: http://www.newscom.com/cgi-bin/prnh/200 8 1022 ... from two Lehigh Valley healthcare leaders, Good S h epherd ... nc. (B. Braun), which are combining their knowledge, expertise and innovative ...
    Cached Biology Technology:Avid Bioservices Expands Executive Team as it Prepares for Continued Growth 2Avid Bioservices Expands Executive Team as it Prepares for Continued Growth 3Avid Bioservices Expands Executive Team as it Prepares for Continued Growth 4Avid Bioservices Expands Executive Team as it Prepares for Continued Growth 5Clinical Trials Offices Changing Academic Health Center Research Infrastructure 2Two Lehigh Valley Healthcare Leaders Collaborate to Deliver Safer, High-Quality Care to the Community 2Two Lehigh Valley Healthcare Leaders Collaborate to Deliver Safer, High-Quality Care to the Community 3Two Lehigh Valley Healthcare Leaders Collaborate to Deliver Safer, High-Quality Care to the Community 4
    (Date:4/17/2014)... in the Amazon help create tinderbox conditions for ... widespread forest loss during drought years, according to ... forests in the Amazon could reach a "tipping ... lead to large-scale loss of trees, making recovery ... geography, Penn State. , "We documented one of ...
    (Date:4/17/2014)... painted a stark warning on the possible effects of ... effect 32 times that of carbon dioxide. Now a ... act as fully regenerable electron acceptors which helps explain ... instead of being released to the atmosphere. However, there ... may enter into a vicious cycle to release large ...
    (Date:4/17/2014)... genetic information of DNA is used to manufacture ... different functions in living organisms. Messenger RNA (mRNA) ... by relating the genetic information of DNA to ... , By examining the different types and amounts ... a given time, researchers can determine which specific ...
    Breaking Biology News(10 mins):Drought and fire in the Amazon lead to sharp increases in forest tree mortality 2Drought and fire in the Amazon lead to sharp increases in forest tree mortality 3Methane climate change risk suggested by proof of redox cycling of humic substances 2Rapid and accurate mRNA detection in plant tissues 2
    ... ARBORResearchers at the University of Michigan,s School of Natural ... study of disparities in access to healthy food across ... study data in 18 small to mid-sized cities to ... term that defines easy access to safe and healthy ...
    ... one of the experts who are currently working in ... Change (IPCC) assessment report on climate change. The report ... response strategies in the area of climate change mitigation ... Sterner is one of 281 experts from 56 different ...
    ... factors responsible for symptoms such as headaches, gastro-intestinal disorders, ... unconsciousness and cardiac arrhythmia in severe cases. Histamine, one ... cause serious physical problems. Biogenic amines can be produced ... also ingested in larger quantities with food. They play ...
    Cached Biology News:U-M researchers to study 'food security' across Michigan 2Development of measures to prevent wine indispositions 2
    Human Legumain Affinity Purified Polyclonal Ab...
    Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
    Human Cystatin F MAb (Clone 292103)...
    Rat CNTF R alpha Affinity Purified Polyclonal Ab...
    Biology Products: